Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Multiple Myeloma 16Leukemia, Myeloid, Acute 16Myelodysplastic Syndromes 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 9Leukemia 8Burkitt Lymphoma 8Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 6Hodgkin Disease 6Congenital Abnormalities 6Sarcoma 5Recurrence 5Neoplasms, Plasma Cell 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Central Nervous System Neoplasms 4Breast Neoplasms 4Wilms Tumor 3Retinoblastoma 3Neuroblastoma 3Neoplasm Metastasis 3Myeloproliferative Disorders 3Medulloblastoma 3Lymphoma, Large-Cell, Immunoblastic 3Leukemia, Myelomonocytic, Juvenile 3

Interventions

Rituximab 24Cyclophosphamide 10fludarabine phosphate 8Bortezomib 7Lenalidomide 6Tacrolimus 5Mycophenolic Acid 5idelalisib 4ibrutinib 4Peripheral Blood Stem Cell Transplantation 4Antilymphocyte Serum 4tanespimycin 3Whole-Body Irradiation 3Radiotherapy 3Indium 3Dasatinib 3Cyclosporine 3pomalidomide 2ofatumumab 2nelarabine 2ibritumomab tiuxetan 2Vincristine 2Sirolimus 2Radiation 2Prednisone 2Polymerase Chain Reaction 2Methotrexate 2Melphalan 2Magnetic Resonance Spectroscopy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Waldenstrom Macroglobulinemia × Granulocyte Colony-Stimulating Factor × Clear all
NCT01408043 2019-06-14

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Case Comprehensive Cancer Center

Phase NA Terminated
25 enrolled 15 charts
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT00012298 2018-08-09

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
81 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡